[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
July 2016

Prognostication of Uveal MelanomaA Work in Progress

Author Affiliations
  • 1Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland, Ohio
  • 2Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio
JAMA Ophthalmol. 2016;134(7):740-741. doi:10.1001/jamaophthalmol.2016.1070

In this issue of JAMA Ophthalmology, 2 articles1,2 address important aspects of melanoma: pathogenesis (driver mutations), prognostication, and survival. Genetic alterations detected in the primary tumor by chromosomal tests (fluorescence in situ hybridization), DNA-based tests (single-nucleotide polymorphism and multiplex ligation–dependent probe amplification), and RNA-based tests (gene expression profiling) only reflect tumor determinants of metastases. It has been known for some time that uveal melanoma is not a localized disease, and with suitable techniques, circulating uveal melanoma cells can be detected in the peripheral blood.3 Other as-yet-unknown host defense factors (as detected by analysis of plasma proteins) also play a role.4 The study of mutational events in the samples of metastatic tumors to the liver will yield the missing pieces to complete the puzzle.5

First Page Preview View Large
First page PDF preview
First page PDF preview